Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD
Share
Subscribe
Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.
In today’s episode, we welcomed Quinto Gesiotto, MD, a malignant hematologist at Tampa General Hospital in Florida.
In the exclusive interview, Dr Gesiotto explored the evolving role of TKIs in the treatment of patients with chronic myeloid leukemia (CML), including dosing patterns for ponatinib (Iclusig) in those with CML and other TKI data to emerge in the CML space at the 2025 ASH Annual Meeting and Exposition. Dr Gesiotto also provided detail on emerging data on novel strategies and agents, along with genetic mutations beyond BCR-ABL1 T315I the could drive more personalized treatment sequencing and improved risk stratification in CML in the future.